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Disrupting SUMOylation enhances transcriptional
function and ameliorates polyglutamine androgen
receptor–mediated disease
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Thomas Jefferson University, Philadelphia, Pennsylvania, USA. 5Department of Pharmacology, 6Department of Human Genetics, and 7Department of Computational Medicine and Bioinformatics,
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Expansion of the polyglutamine (polyQ) tract within the androgen receptor (AR) causes neuromuscular degeneration in
individuals with spinobulbar muscular atrophy (SBMA). PolyQ AR has diminished transcriptional function and exhibits
ligand-dependent proteotoxicity, features that have both been implicated in SBMA; however, the extent to which altered
AR transcriptional function contributes to pathogenesis remains controversial. Here, we sought to dissociate effects of
diminished AR function from polyQ-mediated proteotoxicity by enhancing the transcriptional activity of polyQ AR. To
accomplish this, we bypassed the inhibitory effect of AR SUMOylation (where SUMO indicates small ubiquitin-like modifier)
by mutating conserved lysines in the polyQ AR that are sites of SUMOylation. We determined that replacement of these
residues by arginine enhances polyQ AR activity as a hormone-dependent transcriptional regulator. In a murine model,
disruption of polyQ AR SUMOylation rescued exercise endurance and type I muscle fiber atrophy; it also prolonged survival.
These changes occurred without overt alterations in polyQ AR expression or aggregation, revealing the favorable trophic
support exerted by the ligand-activated receptor. Our findings demonstrate beneficial effects of enhancing the transcriptional
function of the ligand-activated polyQ AR and indicate that the SUMOylation pathway may be a potential target for
therapeutic intervention in SBMA.

Introduction

The CAG/polyglutamine (CAG/polyQ) disorders are a family of
9 neurodegenerative diseases caused by similar microsatellite
expansions in coding regions of unrelated genes (1). Among these
diseases is spinobulbar muscular atrophy (SBMA), a progressive
neuromuscular disorder that occurs only in men and is characterized by proximal limb and bulbar muscle weakness, atrophy, and
fasciculations (2). Clinical onset of SBMA occurs in adolescence
to adulthood and is characterized initially by muscle cramps and
elevated serum creatine kinase (3, 4). These myopathic features
commonly precede muscle weakness, which inevitably develops
as the disease progresses. The causative mutation in SBMA is an
expansion of a CAG repeat in the first exon of the androgen receptor (AR) gene (5). The expanded glutamine tract promotes hormone-dependent AR unfolding and oligomerization, steps that are
critical to toxicity. In SBMA, as in other CAG/polyQ disorders, the
mutant protein disrupts multiple downstream pathways and toxicity likely results from the cumulative effects of altering a diverse
array of cellular processes including transcription, RNA splicing,
axonal transport, and mitochondrial function (6–15). Mechanisms
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that lead to the selective impairment of the neuromuscular system
remain incompletely understood, yet recent studies have established that peripheral expression of the polyQ AR in skeletal muscle is an important contributor to this process (16, 17).
In addition to the proteotoxic gain of function, polyQ expansion
also negatively affects the intrinsic transcriptional activity of the AR
(6, 8–10). While SBMA patients exhibit signs of partial androgen
insensitivity, as manifested by diminished fertility and gynecomastia, the extent to which loss of AR function contributes to pathogenesis remains poorly understood, mainly because of the difficulty in
dissociating effects of proteotoxicity from impaired intrinsic transcriptional function. To explore this question, we sought to define
the consequences of mitigating the transcriptional deficits of the
polyQ AR by relieving the inhibitory effect of AR posttranslational
modification by small ubiquitin-like modifier (SUMO) (18, 19).
SUMO proteins share with ubiquitin a common structural
fold and are reversibly conjugated to lysine residues in target proteins through an enzymatic pathway analogous to ubiquitination,
but carried out by a distinct set of enzymes (20). AR was one of
the first proteins shown to be subject to SUMOylation (19), and
this modification occurs at 2 lysines (K385, K518) in the N-terminal region. These residues are embedded within short amino
acid motifs that have been functionally defined in AR and other
sequence-specific factors as exerting a promoter context inhibitory effect (18). As is the case for most proteins, steady-state stoichiometry of SUMOylation of AR is low, likely because of active
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reversal by SUMO proteases such as SUMO1/sentrin-specific peptidase 1 (SENP1) (21). Nevertheless, transient SUMOylation exerts
strong inhibitory effects through a distinct surface in SUMO (22)
that is recognized by SUMO-binding motifs in partner proteins
(23). Although the exact nature of the SUMO-binding factors
responsible for the inhibitory effects on AR is not fully defined,
mechanistic studies indicate that SUMOylation exerts its effects
preferentially on stably bound receptor-DNA complexes (24) and
involves a redistribution of AR away from chromatin (25).
SUMOylation has attracted considerable attention for its
impact on neurodegenerative diseases, including polyQ disorders
(26, 27). In addition to AR, several mutant proteins that cause neurodegeneration are targets of SUMOylation. The extent to which
SUMO influences disease pathogenesis varies in a context-dependent manner (28). Here, we take advantage of the modulatory role
of SUMOylation on AR function to test the hypothesis that diminished transcriptional activity of the polyQ AR contributes to SBMA
pathogenesis. In this view, restoring transcriptional function
would be expected to attenuate some aspects of the disease. Our
approach is based on the established inhibitory effects of SUMO
on AR function, the significant loss of transactivation caused by
polyQ expansion (6–10, 29), and prior studies suggesting that
native AR function contributes to SBMA pathogenesis (30). To
test our hypothesis, we used gene targeting to generate a knockin
mouse line that expresses a polyQ-expanded AR that cannot be
SUMOylated. Our studies characterizing this new mouse model
of SBMA, complemented by additional experimental systems in
vitro, provide a unique avenue for examining the effects of restoring polyQ AR function and serve to dissociate the pathogenic role
of AR dysfunction from polyQ proteotoxicity in vivo.

Results

Establishment of a cellular model of a SUMOylation-resistant polyQ
AR. To study the effects of abrogating SUMOylation of the polyQ
AR, we initially generated PC12 cells expressing tetracyclineregulated AR10Q, AR112Q, and AR111Q, with its 2 SUMO-acceptor lysine residues mutated to arginine (AR111Q-KRKR) (Figure
1A). With these cells, we tested to determine whether introducing mutations that prevent SUMOylation affected the response
of polyQ AR to ligand. In the absence of the synthetic nonaromatizable androgen R1881, all 3 variants of AR displayed a predominantly cytoplasmic distribution, in agreement with expected
localization when unbound to ligand (Figure 1, B and C). Upon
addition of R1881, all 3 AR forms accumulated in the nucleus
with comparable kinetics (Figure 1B) and both AR112Q and
AR111Q-KRKR formed ligand-dependent intranuclear aggregates (Figure 1C). To verify that the KRKR mutations interrupt AR
SUMOylation, we transiently transfected AR112Q and AR111QKRKR cells with HA-tagged SUMO3, then immunoprecipitated
each polyQ AR variant and probed for HA. Western blot analysis confirmed that polyQ AR remained a target of SUMOylation
and that the KRKR mutation prevented this modification (Figure
1D), in line with previous transient expression studies (31). In
contrast, the KRKR mutation did not alter ubiquitination (Figure 1E), another lysine-directed posttranslational modification
of the polyQ AR. Both AR112Q and AR111Q-KRKR were ubiquitinated in cells expressing the human E3 ligase C terminus of
2

Hsc70-interacting protein (hCHIP) and HA-tagged ubiquitin.
Moreover, ubiquitination of both AR variants was enhanced following treatment with YM-1 (Figure 1E), an allosteric regulator
of Hsp70 that increases polyQ AR degradation (32). These data
indicate that the KRKR mutation abolishes SUMO modification
of the polyQ AR without significantly altering ligand-dependent
localization or ubiquitination.
Preventing SUMOylation enhances transcriptional activity of the
polyQ AR. To examine the effects of the KRKR mutation on polyQ
AR transcriptional function, PC12 cells were induced to express
similar levels of AR10Q, AR112Q, or AR111Q-KRKR (as in Figure
1A) and then stimulated with R1881 or vehicle control for 24 hours.
Triplicate RNA samples from each line were collected, and the corresponding cDNAs were analyzed by Affymetrix GeneChip microarrays (Figure 2, A–C). A heat map of the 93 genes significantly activated (in red) or repressed (in blue) by androgen in AR10Q cells and
the corresponding levels in AR112Q and AR111Q-KRKR is shown
in Figure 2A. This analysis confirmed a glutamine length–dependent partial loss of AR function with a significant reduction in the
amplitude of regulation for most genes (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/
JCI73214DS1). Of the 93 ligand-responsive genes identified in
cells expressing AR10Q, only 32 met criteria for ligand regulation
(≥1.5-fold change) in AR112Q cells (Figure 2C). Detailed analyses
revealed that the regulatory deficits in AR112Q cells were broad
across the set of 93 ligand-responsive genes and affected genes irrespective of the relative abundance of their transcripts (not shown).
Notably, and consistent with the promoter context-dependent
effects of AR SUMOylation, disruption of the SUMOylation sites
partially counteracted this polyQ-induced loss of function. AR111QKRKR cells showed enhanced responsiveness to a subset of genes,
increasing the number of genes meeting the threshold for differential expression to 49 (Figure 2C). To confirm these data, we analyzed selected genes by quantitative real-time RT-PCR (qPCR). The
Ppard gene, drawn from the microarray subset of genes regulated in
all 3 lines, displayed comparable induction when analyzed by qPCR
(Figure 2D). In contrast, examination of 2 independent genes from
the subset regulated only by AR10Q and AR111Q-KRKR (Baiap2,
Chst1) confirmed a glutamine length–dependent loss of inducibility
that was reversed and even further enhanced by disruption of the
SUMOylation sites (Figure 2D). This same pattern of androgenresponsive changes was observed in PC12 cells expressing AR10Q
and AR10Q-KRKR (Figure 2E). AR10Q and AR10Q-KRKR displayed similar ligand-dependent activation of Ppard, whereas
AR10Q-KRKR triggered enhanced activation of Baiap2 and Chst1.
These data are consistent with prior studies using reporter gene
assays, where disrupting polyQ AR SUMOylation by introduction of
the KRKR mutations or I384N/V517N substitutions or by deletion
of the SUMOylation motifs enhanced activation of AR- responsive
reporter gene constructs (31).
Notably, we also found that the KRKR mutation enhanced the
total number of genes meeting threshold for ligand responsiveness to 246 (Figure 2C). For the 183 genes that met the threshold
for only AR111Q-KRKR, a comparison with the corresponding
levels in AR10Q and AR112Q (Figure 2B) revealed that a large
majority of these genes displayed ligand regulation but did not
change by 1.5-fold or more (Supplemental Table 2). This outcome
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Figure 1. A cellular model expressing non-SUMOylatable polyQ AR. (A) AR10Q, AR112Q, or AR111Q-KRKR were induced to express AR in the presence of 10 nM
R1881 for 24 hours, then analyzed by Western blot. Dox, doxycycline. (B and C) AR10Q, AR112Q, and AR111Q-KRKR cells were induced to express AR for 24 hours,
then treated with R1881 for varying times and immunostained for AR (red). Nuclei were stained by DAPI. (B) Cytoplasmic (score 0) to nuclear (score 4) translocation was determined at indicated times. Data are mean ± SEM. n = 3 replicate experiments. (C) Arrows indicate nuclei containing aggregates after 24 hours of
treatment with 10 nM R1881. Scale bar: 2 μm. (D) AR112Q- and AR111Q-KRKR–expressing cells were transfected with HA-SUMO3 and treated with 10 nM R1881
for 24 hours. Whole-cell lysates (left panel) were immunoprecipitated for AR and blotted for HA or AR (right panel). (E) AR112Q or AR111Q-KRKR cells were transfected with HA-ubiquitin and hCHIP, and treated with YM-1, as indicated. Following incubation with 10 mM MG132, lysates were collected and analyzed for AR
ubiquitination. Whole-cell lysates (left panel) were immunoprecipitated for AR and blotted for AR and HA (middle and right panels).

is consistent with the predicted enhancement in responsiveness
to a subset of genes natively regulated by AR as a consequence
of relief from the inhibitory effects of SUMO. These findings are
also similar to those recently reported in a prostate cancer cell
line where the KRKR mutation (in non–polyQ-expanded AR) was

found to expand the number of induced and repressed genes (33).
Taken together, these results demonstrate that, although expansion of the glutamine tract diminishes the responsiveness of genes
normally regulated by AR, preventing SUMOylation through the
KRKR mutation partially counteracts these deleterious effects.
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Figure 2. Disruption of polyQ AR SUMOylation potentiates AR function. (A) Heat map showing expression of genes activated (red) or repressed (blue)
1.5-fold or more by AR10Q cells compared with expression in AR112Q and AR111Q-KRKR cells. (B) Heat map showing expression of 183 androgen-responsive
genes in AR111Q-KRKR cells that change less than 1.5-fold in AR10Q and AR112Q cells. (C) Venn diagram illustrating the number and overlap of androgenresponsive genes in AR10Q (black circle), AR112Q (blue circle), and AR111Q-KRKR cells (red circle). (D) Expression of candidate genes (Ppard, Baiap2, and
Chst1 in black, red, and purple, respectively) identified in A was analyzed by qPCR. Data shown are mean ± SEM (n = 3). ****P < 0.0001 by ANOVA. (E)
Expression of candidate genes (Ppard, Baiap2, and Chst1 in black, red, and purple, respectively) in AR10Q and AR10Q-KRKR cells was analyzed by qPCR.
Data shown are mean ± SEM (n = 3). **P < 0.01; ***P < 0.001; ****P < 0.0001 by ANOVA.

Generation of AR113Q-KRKR knockin mice. To investigate the
influence of SUMOylation in vivo, we used gene targeting in order
to generate knockin mice that express the polyQ AR, with K385 and
K518 both mutated to arginines. We modified the targeting vector
used previously to generate our existing AR113Q line of knockin
mice by introducing the KRKR mutations (Figure 3A). We verified
correct recombination of the targeted exon 1 into the mouse AR
gene by Southern blot analysis in JM8.F6 cells, an embryonic stem
(ES) cell line from the C57BL/6N strain (Figure 3B). After germline
transmission of the targeted allele from chimeric founders to F1 heterozygous females, we crossed these females to C57BL/6J WT males
and assessed subsequent inheritance of the AR113Q-KRKR allele by
PCR (Figure 3C). For the purposes of phenotypic characterization in
this study, we used AR113Q male mice backcrossed for more than
10 generations to the C57BL/6J background, N1 AR113Q-KRKR
male mice, and WT littermate males from both lines. Females from
both AR113Q lines were similarly fertile, and both AR113Q alleles
were inherited in the expected Mendelian ratios (data not shown).
Male mice from the AR113Q and AR113Q-KRKR lines were indistinguishable prior to disease onset at sexual maturity.
Preventing AR SUMOylation alters ligand-dependent gene regulation in vivo. We initially sought to determine the consequences of
4

disrupting AR SUMOylation on ligand-dependent gene regulation
in vivo. To accomplish this, a cohort of WT, AR113Q, and AR113QKRKR adult males were surgically castrated in order to suppress
endogenous ligand activation of AR. Three weeks after orchiectomy, animals were treated with testosterone propionate or vehicle by
i.p. injection and tissues were harvested after 16 hours. The expression of well-characterized androgen-induced genes in prostate was
examined by qPCR (Figure 4A). Our analysis showed that the strong
ligand-induced expression of Nkx3-1 in WT males was absent in the
AR113Q line, but was fully restored in AR113Q-KRKR mice. A similar pattern was also observed for Fkbp5. In the case of Pbsn, the modest and not significant induction in WT males was absent in ARQ113
mice, but was strongly enhanced in AR113Q-KRKR mice. To determine effects on androgen-regulated gene expression in skeletal
muscle, we harvested the levator ani-bulbocavernosus (LABC), a
muscle that expresses high levels of AR. We used an AR-signaling
target array to identify candidate androgen-responsive genes in
muscle from WT mice (data not shown). We selected 7 genes that
were repressed by ligand treatment and confirmed that all transcripts were significantly decreased in muscle following androgen
treatment of WT males (Figure 4B). In AR113Q males, none of these
genes responded to androgen treatment, whereas appropriate regu-
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Figure 3. Generation of AR113Q-KRKR knockin
mice. (A) Schematic representation depicting
AR113Q-KRKR targeting vector. Sphl restriction
sites, 5′ and 3′ probes for Southern blot analysis,
glutamine tract, lysine-to-arginine mutations, and
floxed neomycin resistance cassette are indicated.
Diagram modified from ref. 55. (B) Southern blot
analysis of ES cell DNA after Sphl digestion with
the 5′ and 3′ probes indicated in A before (lanes
1 and 4) and after (lanes 2 and 5) homologous
recombination. Lanes 3 and 6 contain control liver
DNA from previously targeted AR113Q knockin line.
L, ladder. (C) PCR primers were used to amplify
sequences from a WT female (lane 1), F1 AR113QKRKR female (lane 2), and N1 AR113Q-KRKR male
(lane 3) produced by the female in lane 2.

lation was observed in AR113Q-KRKR males. Taken together, these
data are consistent with our PC12 cellular model and demonstrate
that disrupting polyQ AR SUMOylation restores acute androgen
responsiveness to AR target genes in vivo.
AR113Q-KRKR males demonstrate partial androgen compromise. Since partial loss of AR function and features of androgen
insensitivity are molecular and phenotypic hallmarks of SBMA,
we examined several measures of androgen function on the hypothalamic-pituitary-gonadal (HPG) axis in AR113Q-KRKR mice at
13 to 15 weeks of age. Compared with WT mice, both AR113Q and
AR113Q-KRKR mice demonstrated testicular and seminal vesicle
atrophy and reduced sperm counts (Figure 5A). Modest elevations in serum testosterone and luteinizing hormone (LH) were
evident in both AR113Q and AR113Q-KRKR males, but because of
variability between animals, these changes did not reach statistical significance (Figure 5B). We also analyzed testicular expression of the gene encoding 3-β-hydroxysteroid dehydrogenase
type I (3βHSD-I, Hsd3b1), an enzyme responsible for ketosteroid
hormone synthesis in Leydig cells in response to LH and whose
expression is indicative of androgen insensitivity (34). Consistent
with the endocrine tissue pathology and serum studies, we found
similar increases in Hsd3b1 mRNA in testes from both 113Q lines
of mice (Figure 5C). These data demonstrate that compromise of
the androgen axis remains evident when polyQ AR SUMOylation
is prevented. Furthermore, we speculated that chronically
enhanced AR activity in the KRKR mutant could lead to inhibition
of the HPG axis in aged males. Consistent with this notion, adult
AR113Q-KRKR males at 7 to 9 months exhibited more severe testicular atrophy and decreased sperm counts compared with similarly aged AR113Q males (Figure 5D).
Behavioral and neuromuscular phenotypes in AR113Q-KRKR
mice. As the phenotype of AR113Q mice includes decreased body
mass and grip strength, we also evaluated these parameters in
AR113Q-KRKR mice and found indistinguishable deficits (Figure
6, A and B). The reduction in these measures became evident at
approximately 12 weeks and persisted thereafter. To broaden our

characterization of muscle function beyond assessment of grip
strength, we examined exercise capacity by treadmill running
until exhaustion. By this measure we detected a significant decrement in exercise endurance in AR113Q mice (Figure 6C), consistent with other measures of functional decline in SBMA muscle
(35, 36). Strikingly, KRKR mutations in the polyQ AR yielded a
profound rescue of exercise capacity to levels equivalent to those
of WT mice. This functional rescue persisted in mice aged up to 9
months (Figure 6D). Since many trophic effects of androgens on
muscle are thought to be a consequence of ligand-activated gene
regulation, we hypothesized that the recovery in KRKR mutants
reflected a restored trophic support that would be dependent
upon ligand. To test this possibility, we applied the same exercise
paradigm to AR113Q-KRKR males that had been castrated at 5
to 6 weeks and to WT females. Exercise trials of these 2 cohorts
revealed substantially less exercise capacity compared with
gonadally intact males regardless of glutamine tract length (Figure 6C). These results confirmed the supportive role of androgens
in the development of exercise endurance and in directing the rescue in SUMO-resistant SBMA mice.
Since early death is another phenotypic feature of AR113Q
mice, we followed cohorts of WT, AR113Q, and AR113Q-KRKR
mice and monitored survival rates. In line with previous characterization (36), AR113Q mice demonstrated a precipitous decline
in survival beginning at 13 weeks (Figure 6E). None of these mice
survived past 40 weeks (n = 10). In contrast, AR113Q-KRKR mice
exhibited a profound extension of life span. Through 40 weeks,
only 1 death occurred in the experimental cohort (n = 10). This
rescue of early death was significant (P < 0.0001) and took place
despite a lack of discernible differences in disease onset between
the SUMOylation-competent and SUMOylation-deficient AR113Q
lines. We defined disease onset as the age at which grip strength
of mutant males was 10% less than the mean of age-matched WT
controls and found no difference between AR113Q and AR113QKRKR males (Figure 6E). Accordingly, the equivalent disease
onset coupled with life span extension resulted in a significant
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Figure 4. Expression of androgen-responsive genes in prostate and skeletal muscle. WT (black bars), AR113Q (white bars), and AR113Q-KRKR (gray bars)
adult males underwent orchiectomy and then 3 weeks later were treated with 200 mg testosterone propionate i.p. (+) or vehicle (–). Prostate (A) and LABC
muscle (B) were harvested after 16 hours. Expression of AR-responsive genes was analyzed by qPCR. Data shown are mean ± SEM (n = 3/group). *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant by ANOVA.

extension of disease duration (P < 0.02) in the SUMOylation-deficient SBMA mice (Figure 6E). Taken together, these results show
that abrogating polyQ AR SUMOylation, which enhances AR transcriptional function, exerts profound and long-lasting beneficial
effects on exercise endurance and survival.
Rescue of type I fiber atrophy and gene-expression changes in
AR113Q-KRKR muscle. To explore the mechanism underlying
phenotypic rescue in AR113Q-KRKR mice, we initially sought to
determine whether mutant forms of the AR were equivalently
expressed. Immunoprecipitation (IP) of AR from quadriceps
muscle and spinal cord demonstrated that levels of AR113Q and
AR113Q-KRKR were similar (Figure 7A and Supplemental Figure
1). Comparable levels of AR protein were also detected in testis
of WT, AR113Q, and AR113Q-KRKR mice (Figure 7B and Supple6

mental Figure 1). Since AR113Q mice display frequent accumulation of intranuclear aggregates of polyQ AR in skeletal muscle
(36), we analyzed sections of LABC and quadriceps muscle from
mice aged 13 to 15 weeks. While quadriceps nuclei in WT muscle
rarely showed punctate AR intranuclear staining (5.5% ± 2.3%),
nuclei from both AR113Q and AR113Q-KRKR quadriceps muscle
showed substantially higher and similar amounts of polyQ AR
aggregates (26.9% ± 2.2% and 29.4% ± 1.9%, respectively) (Figure
7C). A similar pattern was observed in the LABC. These analyses
indicate that phenotypic rescue was not attributable to diminished
expression or aggregation of AR113Q-KRKR.
Rescue of exercise endurance and survival was also not associated with attenuation of muscle atrophy or skeletal muscle
gene-expression changes indicative of denervation. The tibialis
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Figure 5. Characterization of the HPG axis in AR113Q-KRKR mice. (A) Testes and seminal vesicles were collected at 13 to 15 weeks and analyzed by weight
(left and middle panels). Epididymes were collected and sperm count determined (right panel). Data are shown as mean ± SEM (n = 6 per group). *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001 by ANOVA. (B) Serum samples (n = 6 per group) were collected at 13 to 15 weeks and analyzed for levels of testosterone (T) and LH. Data are shown as mean ± SEM. (C) Total RNA was extracted from testes from WT, AR113Q, and AR113Q-KRKR mice (n = 3 per group) at
13 to 15 weeks and analyzed for Hsd3b1 expression by qPCR. Data are shown as mean ± SEM. ****P < 0.0001 by ANOVA. (D) Testis weight and epididymal
sperm count from males at 7 to 9 months. Data are shown as mean ± SEM. *P < 0.05; ***P < 0.001; ****P < 0.0001 by ANOVA.

anterior (TA) muscle showed significant atrophy in both AR113Q
and AR113Q-KRKR mice compared with WT (Figure 8A). Both
AR113Q lines expressed equivalent levels of AR mRNA and
showed increased expression of acetylcholine receptor-α subunit
and myogenin mRNAs in quadriceps muscle. A similar trend was
observed for the expression of Myod mRNA (Figure 8B). Unexpectedly, these measurements of muscle pathology were slightly
accentuated in AR113Q-KRKR mice despite rescue of exercise
capacity and survival. This suggested that alterations in other
muscle properties mediated the beneficial response to ligand activation of AR113Q-KRKR.
An important determinant of exercise performance and metabolic profile is the fiber type composition of skeletal muscle. Type I
(slow twitch) fibers are rich in mitochondria, fatigue resistant, and
reliant on oxidative metabolism, while type II (fast twitch) fibers
are mitochondria poor, fatigue susceptible, and dependent on glycolytic metabolism (37, 38). Given the notable androgen-dependent improvement in exercise endurance in AR113Q-KRKR males,
we performed immunostaining for fiber type–specific heavy-chain
myosins on soleus muscle because of its mixed fiber type composition. In contrast, both the TA and quadriceps muscles are type II
fiber predominant (39, 40). In AR113Q soleus muscle, we observed
atrophy across all fiber types (Figure 8, C and D). In contrast, soleus
from AR113-KRKR mice contained type I fibers that were remarkably spared from atrophy (Figure 8, C and D). Quantification of
cross-sectional area demonstrated a significant rescue in the distribution and mean type I fiber size (Figure 8D). This rescue of muscle
atrophy was not seen in type II fibers of AR113Q-KRKR muscle, nor
was it observed in type I fibers of AR113Q-KRKR mice following
castration (Figure 8D). These data reveal that the improved exer-

cise endurance in AR113Q-KRKR was associated with rescue of
type I fiber atrophy and suggest that this fiber-selective effect is
mediated by trophic support from the KRKR receptor.
To explore whether AR113Q-KRKR also affects muscle predominantly composed of type II fibers despite the absence of morphological rescue of atrophy, we used RNA-Seq to analyze gene
expression in quadriceps muscle from WT, AR113Q, and AR113QKRKR males at 14 weeks. Pairwise comparisons enabled the identification of differentially expressed genes in WT versus AR113Q
muscle and WT versus AR113Q-KRKR muscle. We queried these
lists against a publicly available database of literature-derived
androgen-responsive genes that includes 993 mouse genes (41).
This strategy identified 107 differentially expressed androgenresponse genes in quadriceps muscle of WT versus AR113Q males
(Figure 9A and Supplemental Table 3). Ninety-six of these genes
were also differentially expressed in WT versus AR113Q-KRKR
muscle. As shown in the heat map (Figure 9B), similar expression
changes were identified for the majority of these genes in AR113Q
and AR113Q-KRKR muscle, though AR113Q-KRKR muscle generally showed a greater magnitude of change. Interestingly, this
analysis also identified an additional 221 genes that were differentially expressed in AR113Q-KRKR, but not AR113Q muscle (Figure
9, A and B), suggesting that the mutation had expanded the set of
AR-regulated genes in skeletal muscle much as it had done in vitro
(Figure 2). Pathway analysis using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) revealed that
these 221 genes were highly enriched for mitochondria-related
functional categories (Table 1), indicating that altered expression
of genes regulating energy metabolism correlated with enhanced
exercise endurance. Taken together, these data suggest that dis-
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Figure 6. Phenotypic characterization of
AR113Q-KRKR knockin mice. (A) WT, AR113Q,
and AR113Q-KRKR male mice (n = 10 per group)
were weighed and (B) assessed for forelimb
grip strength every 2 weeks. Data shown are
mean ± SEM. (C) WT (n = 7), AR113Q (n = 6),
AR113Q-KRKR male mice (n = 6), castrated
AR113Q-KRKR males (AR113Q-KRKR-C, n = 4),
and WT females (n = 4) were exercised until
exhaustion at 13 to 15 weeks of age, and total
time and distance run were recorded. Data are
mean ± SEM. *P < 0.05; **P < 0.01 by ANOVA.
(D) WT, 113Q, and 113Q-KRKR (n = 3 per group)
males were exercised until exhaustion at 7 to 9
months of age, and total time and distance run
were recorded. Data are mean ± SEM. *P < 0.05
by ANOVA. (E) WT, AR113Q, and AR113Q-KRKR
male mice (n = 10 per group) were followed for
overall survival (left panel, P < 0.0001 113Q vs.
113Q-KRKR by Mantel-Cox log-rank test), and
both 113Q knockin mouse lines were monitored
for disease onset (middle panel, P = 0.6) and
disease duration (right panel, P < 0.02).

ruption of AR113Q SUMOylation promotes hormone-dependent
trophic effects on skeletal muscle mediated by enhanced activity
of the receptor as a transcriptional regulator.

Discussion

In this study of SBMA pathogenesis, we sought to disentangle
polyQ length–dependent proteotoxicity from the partial loss of AR
function to discern the relative contribution of each mechanism to
the disease. To accomplish this goal, we selectively counteracted
functional alterations in the polyQ AR by relieving the transcriptional inhibitory effect of SUMOylation. We show that mutation
of the SUMO-acceptor sites in AR exon 1 specifically prevents
SUMOylation of polyQ AR without altering ligand-induced nuclear translocation, formation of intranuclear inclusions, or steadystate protein levels. Consistent with the established repressive role
of SUMO on AR function, the SUMOylation-deficient polyQ AR
displays broadly enhanced transcriptional activity in both cell culture and mice, with a profile that partially counteracts the polyQmediated loss of function. Male mice generated by gene targeting
to express AR113Q-KRKR develop normally and express a phenotype only after reaching sexual maturity.
Intriguingly, AR113Q-KRKR male mice exhibit a substantial
recovery of exercise capacity compared with AR113Q males. This
rescue persists as animals age despite decrements in exercise
fitness across all genotypes. Moreover, this rescue is hormone
dependent and is associated with recovery of type I muscle fiber
size, demonstrating that ligand-dependent activation of AR113QKRKR provides marked trophic support to muscle. It is likely that
ligand activation of AR113Q-KRKR exerts beneficial effects on
8

type II muscle fibers as well, despite the lack of rescue of fiber
atrophy. This conclusion is supported by the identification of
numerous gene-expression differences in quadriceps muscle of
AR113Q-KRKR versus WT males that are not similarly detected
in AR113Q muscle, many of which cluster in mitochondria-related pathways. Included in the list of genes selectively upregulated
in AR113Q-KRKR muscle are those encoding the mitochondrial
proteins translocase of mitochondrial membrane 20 homolog
(TOMM20), NADH dehydrogenase (ubiquinone) Fe-S protein
3 (NDUFS3), hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase, β subunit (HADHB), cytochrome
c, and cytochrome oxidase subunit VIIc. The beneficial effects of
the KRKR mutation within skeletal muscle are consistent with
recent studies demonstrating a critical role of peripheral polyQ
AR expression in SBMA pathogenesis (16). The KRKR mutation
within the polyQ AR also leads to an almost complete rescue of
early death and a marked extension of disease duration. As the
phenotypic rescue of AR113Q-KRKR males occurs without evidence of diminished polyQ AR expression or aggregation and is
hormone dependent, we conclude that the beneficial effects of
abrogating SUMOylation are mediated by enhanced transcriptional function of the mutant receptor. Notably, the conclusion
that ligand activation of the receptor’s transcriptional function
is beneficial to SBMA mice is distinct from that drawn from an
analysis of a Drosophila model of SBMA in which native function
of the AR was implicated as indispensable for disease pathogenesis (30). In contrast, our analyses demonstrate that disrupting
polyQ AR SUMOylation enhances its transcriptional function
and rescues key aspects of SBMA pathology. These results argue

jci.org

Downloaded from http://www.jci.org on January 26, 2015. http://dx.doi.org/10.1172/JCI73214

Research article

The Journal of Clinical Investigation  

Figure 7. Expression and aggregation of AR113Q and AR113Q-KRKR are
similar. (A) AR expression in quadriceps and spinal cord from WT, AR113Q,
and AR113Q-KRKR mice was analyzed by IP and Western blot. GAPDH
shows similar input protein levels. (B) AR expression in testis. Hsp90
controls for loading. (C) Immunofluorescence staining for AR (red) in quadriceps and LABC. Nuclei were stained by DAPI (blue). Scale bar: 25 μm. At
right, percentage of nuclei with AR-reactive puncta in the quadriceps. Data
are mean ± SEM. n = 3 mice per genotype. ****P < 0.0001 by ANOVA.

against a purely propathogenic role of native AR function in disease. As Drosophila lack endogenous androgen-responsive genes,
this model is likely insensitive to trophic actions mediated by the
ligand-activated receptor.
Not all aspects of the phenotype of AR113Q males are rescued in AR113Q-KRKR mutants. Disruption of SUMOylation
fails to significantly modify certain aspects of muscle pathology,
including weight of muscles that are primarily composed of type
II fibers, grip strength, and gene-expression changes indicative
of denervation. Although type I fibers are only a small fraction
of overall skeletal muscle mass in mice, they are much more
abundant in humans (42), suggesting that strategies to target
AR SUMOylation may have greater beneficial effects in SBMA
patients. It is also likely that trophic effects of the ligand-activated AR113Q-KRKR are beneficial to additional cell types and
that these actions could contribute to overall health of SBMA
mice. This suggests that activating androgen-regulated trophic pathways that are stimulated by the KRKR receptor may
be beneficial to SBMA patients. A potential approach would be
to suppress SUMO modification of AR by inhibiting the activity
of E3 ligases, such as members of the protein inhibitor of activated STAT (PIAS) family (43), or by stimulating the activity of
SENP1, the main SUMO peptidase responsible for deconjugating
SUMO from AR (44). We are actively pursuing the discovery of
agents that can regulate the activity of these enzymes. Alternatively, selective AR modulators (SARMS) that exert strong anabolic effects in skeletal muscle, but show limited activity in other

organs, could be considered. Whether such SARMS can provide
beneficial effects to muscle in a manner that outweighs liganddependent proteotoxicity awaits future testing.
Unexpectedly, endocrine pathology, including seminal vesicle
and testicular atrophy, sperm count, and Hsd3b1 mRNA expression
are unaffected by AR SUMOylation. These findings raise the possibility that proteotoxicity of the polyQ AR, and not simply partial loss
of transactivation function, contributes to deficits in the HPG axis, a
conclusion that is in accordance with our earlier analysis of AR113Q
mice (45). Alternatively, the HPG axis may be particularly sensitive to
altered regulation of AR target genes by the SUMOylation-deficient
AR, perhaps due to tissue-specific differences in AR SUMOylation.
This latter view is consistent with the androgen-insensitivity phenotype of patients with perturbed AR SUMOylation due to germline
mutations in the first SUMOylation motif of AR (46).
Prior studies have suggested a modulatory role for SUMO
in models of SBMA. Disrupting overall SUMOylation worsens
the SBMA phenotype in a Drosophila model (47), and enhancing
SUMOylation reduces polyQ AR aggregates, which are thought
to reflect protein unfolding and the process that underlies proteotoxicity (31). We suspect that our results are not inconsistent
with these findings. The Drosophila study used an amino-terminal
fragment of the AR that lacks the SUMOylation sites and ligandbinding domain to define effects from global impairment of the
SUMO pathway. This contrasts with the specific modulation of
AR SUMOylation reported here. Similarly, the inhibitory effects of
AR SUMOylation on aggregation require a high stoichiometry of
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Figure 8. Rescue of type I fiber atrophy in AR113Q-KRKR males. (A) TA muscles were harvested from both hind limbs and weighed (n = 6 per group).
Data are mean ± SEM. **P < 0.01; ****P < 0.0001 by ANOVA. (B) AR (Ar), nicotinic acetylcholine receptor-a subunit (Chrna1), myogenin (Myog), and MyoD
(Myod) mRNA were analyzed in quadriceps by qPCR (n = 6 per group). *P < 0.05; ***P < 0.001; ****P < 0.0001 by ANOVA. (C) Representative type I
slow-twitch heavy-chain myosin (green) and type II fast-twitch heavy-chain myosin (red) staining in soleus. Basement membrane stained with wheat
germ agglutinin (green). Scale bar: 50 μm. (D) Mean area ± SEM and fiber size distribution of type I and type II fibers (n = 3 mice per group, ≥75 fibers per
mouse). **P < 0.01; ****P < 0.0001 by ANOVA.

modification. Thus, in cell culture, introducing the KRKR mutations into the AR without inducing high levels of SUMOylation
does not modulate polyQ AR aggregation (31), a finding similar to
our observations in vivo (Figure 7C).
Select point mutations in polyQ proteins exert varying influence on pathogenesis by modifying protein localization, function, or stability. In spinocerebellar ataxia type 1 (SCA1), disease
is ameliorated by diminishing association of polyQ ataxin-1 with
the transrepressor Capicua through the S776A mutation or by preventing nuclear transport through nuclear localization sequence
disruption (48, 49). Consistent with these studies, phosphomimetic S776D ataxin-1 recapitulates toxicity, and pathogenic S776
phosphorylation and subsequent nuclear transport are prevented
by association with 14-3-3 (50, 51). In SCA7, point mutations in
the NES signal of polyQ ataxin-7 reduce nuclear export and exacerbate toxicity (52). Phosphomimetic mutations at Ser13 and
Ser16 in polyQ huntingtin rescue disease and aggregation, while
phospho-null mutations iterate pathogenesis (53). In this regard,
we demonstrate ameliorative effects of KRKR point mutations
in the polyQ AR that modulate AR function without modifying
intracellular localization or aggregation. This new disease model
advances our understanding of SBMA pathogenesis by demonstrating beneficial effects of enhancing function of the polyQ AR
and revealing key features of AR SUMO modification that may be
exploited for therapeutic targeting.
10

Methods

Antibodies. Primary antibodies used for Western blot analysis were
against AR (N-20, Santa Cruz Biotechnology Inc.), Hsp90 (H-114, Santa Cruz Biotechnology Inc.), and HA (HA-11, Covance). Primary antibodies for immunofluorescence were against AR (N-20, Santa Cruz
Biotechnology Inc.), type I/slow-twitch heavy-chain myosin (A4.840,
DSHB, University of Iowa, Iowa City, Iowa, USA), and type II/
fast-twitch heavy-chain myosin (Ab-2, Thermo Scientific). Horseradish peroxidase–conjugated secondary antibodies used for Western
blot analysis were from Bio-Rad. Alexa Fluor 555, Alexa Fluor 488,
and wheat germ agglutinin Alexa Fluor 488 conjugate antibodies
used for immunofluorescence were from Invitrogen. FITC-conjugated donkey anti-mouse IgM was from Jackson ImmunoResearch.
For IP experiments, the anti-AR antibody PG-21 (Millipore) was used,
and pulldown was performed with protein A–agarose beads (Santa
Cruz Biotechnology Inc.).
Cell culture, Western blot, and IP. PC12 cells expressing tetracyclineregulated AR10Q and AR112Q have been described previously (54).
Tet-ON AR111Q-KRKR cells were generated by stable transfection of
pTRE-AR(111-CAG)-KRKR, as described earlier (55). The construct
was generated by excising a portion of p5HB-hAR24Q-KRKR containing the K385R and K518R mutations with NruI/Tth111I and cloning the fragment into pTRE-AR(111-CAG). The codons for K385 and
K518 were AAG and AAA, respectively, and were mutated to codons
for arginine AGA and CGA, respectively. Both K-to-R mutations and
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Figure 9. Gene-expression differences in quadriceps muscle of WT,
AR113Q, and AR113-KRKR males. Muscle was harvested from 14-week-old
males (n = 3/genotype), and gene expression was analyzed by RNA-Seq.
(A) Venn diagram illustrating the number and overlap of differentially
expressed (≥ 1.5-fold) androgen-responsive genes in WT versus AR113Q
(green circle) and WT versus AR113Q-KRKR (red circle). (B) Heat map of
differentially expressed androgen-responsive genes in WT versus AR113Q
or AR113Q-KRKR muscle.

the CAG repeat tract-length were verified by sequencing. Induction of AR expression in AR10Q, AR112Q, and AR111Q-KRKR cells
to equivalent protein levels was performed with 50 ng/ml, 3 ng/ml,
and 500 ng/ml doxycycline (Clontech), respectively, in the presence of 10 nM R1881 or ethanol vehicle for 24 hours unless otherwise
indicated. Cells were grown and passaged on poly-d-lysine–coated
flasks in high-glucose phenol-red–free DMEM (Invitrogen) containing 10% charcoal-stripped horse serum (Invitrogen), 5% charcoalstripped FBS (Atlantic Biologicals), 100 units/ml penicillin/streptomycin (Invitrogen), 200 μg/ml hygromycin B (Invitrogen), and
100 μg/ml G418 (Invitrogen) at 37°C in 10% CO2. For Western blot
analysis, cells were washed twice and collected by cell scraper in
PBS, then lysed in RIPA buffer supplemented with Halt phosphatase
inhibitors (Thermo Scientific), complete protease inhibitors (Roche),
and 20 mM N-ethylmaleimide (Sigma-Aldrich) to irreversibly inhibit
SUMO proteases. Whole-cell lysates were preclarified by centrifugation at 15,000 g for 15 minutes at 4°C. Protein concentrations

were determined by modified protein assay (Bio-Rad). After boiling
at 100°C for 5 minutes in loading buffer, all protein samples were
resolved on 7% or 10% SDS-PAGE gels, transferred to nitrocellulose
membranes on a semi-dry transfer apparatus (Bio-Rad), and probed
by the indicated antibodies. Detection was performed by chemiluminescence. For IP, 1500 μg of protein lysate from mouse tissues in
500 μl of RIPA buffer was incubated with 10 μg of PG-21 antibody
overnight at 4°C. Protein A–agarose beads were prewashed 3 times in
RIPA, then incubated in IP samples for 1 hour at 4°C. Bead-antibody
complexes were then centrifuged in filtered spin columns (Thermo
Scientific), washed 4 times in lysis buffer, and eluted by boiling in
loading buffer for 5 minutes at 100°C. Testis lysates were obtained
by homogenization and centrifugation at 13,000 g for 10 minutes at
4°C. Protein concentrations were determined as described above, and
lysates were resolved on a 7.5% SDS-PAGE gel.
AR ubiquitination and SUMOylation studies. For analysis of ubiquitination, PC12 cells expressing AR112Q or AR111Q-KRKR were plated
at 4 × 106 cells in a poly-d-lysine–coated 60-mm dish (BD Falcon) and
transiently transfected with plasmids encoding hCHIP (1.5 μg) and
HA-His-ubiquitin (4.5 μg) using Lipofectamine 2000 (Life Technologies). Cells were treated with 1 μg/ml doxycycline and 10 nM R1881
and then with 1 μM YM-1 (last 24 hours) and 10 μM MG132 (last 16
hours). 48 hours after transfection, cell pellets were resuspended in
IP lysis/wash buffer (0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1%
NP-40, 5% glycerol; pH 7.4) containing 1 tablet/10 ml of complete
Mini-Protease Inhibitor Mix (Roche) and 5 mM N-ethylmaleimide.
Samples were sonicated and centrifuged at 13,000 g for 10 minutes at
4°C. 400 μg of protein lysate was incubated on a rotator overnight at
4°C with 2 μg of anti-AR antibody (Santa Cruz Biotechnology Inc.) or
nonimmune rabbit IgG. 20 μl of prewashed protein A–agarose beads
(Santa Cruz Biotechnology Inc.) was added, and samples were incubated for 1 additional hour at 4°C. Protein-antibody-bead complexes
were washed 6 times in IP lysis/wash buffer in filtered spin columns
(Thermo Scientific), and proteins were eluted by boiling in SDS-loading buffer for 5 minutes at 100°C. A similar protocol was followed for
analysis on SUMOylation, except that cells were transfected with plasmid encoding HA-SUMO3. Lysates were collected 24 hours after the
addition of 1 μg/ml doxycycline and 10 nM R1881 in IP lysis/wash buffer containing 20 mM N-ethylmaleimide.
Generation of knockin mice. Knockin mice with AR allele containing 113 CAG repeats were derived using gene targeting as described
previously (56). To generate AR113Q-KRKR mice, this strategy was
modified by using the previously described AR113Q-targeting vector
as a template. Briefly, a portion of p5HB-hAR24Q-KRKR containing
the K385R and K518R mutations was excised as an NruI/XhoI fragment and cloned into pLP1-AR113Q. The codons for K385 and K518
were AAG and AAA, respectively, and were mutated to codons for
arginine AGA and CGA, respectively. Both K-to-R mutations and the
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flash frozen in liquid nitrogen for biochemical analysis
or mounted on OCT blocks for cryosectioning. Epididymes were also collected at this time, minced in 4 ml of
PBS, incubated for 10 minutes at room temperature with
GO term
Gene no.
P value (Bonferroni)
–8
gentle agitation, centrifuged for 1 minute at 500 g, and
Mitochondrion
49
3.43 × 10
applied to a hemacytometer to determine sperm counts.
Mitochondrial part
29
1.30 × 10–7
For tissue analyses, quadriceps muscle and lumbar spinal
Mitochondrial envelope
22
2.07 × 10–5
Mitochondrial inner membrane
18
1.49 × 10–4
cord were minced, lysed by agitation at 4°C for 1 hour,
Mitochondrial membrane
20
1.61 × 10–4
and homogenized in RIPA buffer containing phosphatase
Organelle inner membrane
18
3.08 × 10–4
and protease inhibitors. Tissue lysates were then clarified
Generation of precursor metabolites and energy
16
3.89 × 10–3
at 13,000 g for 10 minutes at 4°C. Protein concentrations
Electron transport chain
11
4.01 × 10–3
were determined by modified protein assay (Bio-Rad).
Oxidation reduction
26
6.30 × 10–3
Measurement of serum hormone levels. Serum was colRespiratory chain
8
6.49 × 10–3
lected from mice at 13 to 15 weeks by cardiac puncture,
GO, Gene Ontology.
and testosterone and LH levels were determined by
radioimmunoassay (RIA) and sandwich assay, respectively, by the University of Virginia Center for Research
in Reproduction Ligand Assay and Analysis Core Facility
(Charlottesville, Virginia, USA). The sensitivities of the testosterone
CAG repeat tract-length was verified by sequencing. The modified
RIA and LH assay were 10 ng/dl and 0.07 ng/dl, respectively.
targeting construct containing amino acids 31–484 of human AR exon
Exercise studies. To analyze exercise capacity, a protocol for tread1 and K385,518R mutations replaced mouse AR exon 1 by homolomill running was used as previously described (58). First, mice undergous recombination in JM8.F6 ES cells (57). Correct targeting of the
went 2 days of training on an Exer3/6 treadmill (Columbus InstruAR113Q-KRKR allele was verified through Southern blot analysis
ments), with day 1 consisting of 5 minutes of running at 8 m/min and
using 5′ and 3′ probes falling outside of the targeted construct (Figday 2 consisting of 5 minutes of running at 8 m/min followed by 5 minure 2A). Three clones of correctly targeted ES cells were selected by
utes at 10 m/min. On day 3, mice ran using a graded protocol consistneomycin resistance, karyotyped to verify euploidy, transiently transing of 10 m/min for 40 minutes, then increasing speed by increments
fected with Cre recombinase to excise the floxed neomycin resistance
of 1 m/min every 10 minutes for a total of 30 minutes, and followed by
cassette, and injected into C57BL/6J blastocysts obtained from matincreasing speed by increments of 1 m/min every 5 minutes until mice
ing C57BL/6-BrdCr-Hsd-Tyrc females with C57BL/6-BrdCrHsd-Tyrc
were exhausted. Exhaustion was defined as mice making no attempt to
males. These blastocysts were then implanted in pseudopregnant
exercise for 5 seconds. Assessment of endurance in castrated AR113QC57BL/6J females. All ES cell procedures were performed by the UniKRKR males was performed after orchiectomy at 6 weeks of age as
versity of Michigan Transgenic Animal Model Core.
previously described (36). Briefly, following anesthetization with isoMouse breeding and care. ES cell implantations yielded 8 chimeric
flurane, the pelvic area was shaved and opened bilaterally with 1-cm
males in total, which were then mated with albino C57BL/6J females
incisions to reveal testes for removal, then closed with suture material.
(Jackson Laboratory) to sire AR113Q-KRKR F1 female mice heterozygous for the targeted allele. Germline transmission of the targeted
Immunofluorescence analysis. PC12 cells were washed in PBS and
AR allele was indicated by black coat color and confirmed by PCR
fixed in 4% paraformaldehyde for 30 minutes at room temperature.
genotyping. These females were bred to C57BL/6J WT males to genFor quadriceps and soleus muscles, cryosections were prepared using
erate AR113Q-KRKR males for use in this study and AR113Q-KRKR
a Cryocut 1800 cryostat (Leica) at 10 μm. Staining was performed
heterozygous females to maintain the line. Mice were group housed
using the indicated antibodies, mounted using Vectashield medium
in a specific pathogen–free (SPF) facility and provided with chow and
(Vector Laboratories), and sealed with nail polish. We scored AR
water ad libitum. Genotypes were verified by PCR of DNA harvested
translocation from cytoplasm to nucleus as described previously (59,
from tail biopsies obtained shortly after weaning, using the forward
60), using a value of 4 for nuclear fluorescence much greater than
primer 5′-CCAGAATCTGTTCCAGAGCGTG-3′ and the reverse primcytoplasmic fluorescence, 3 for nuclear fluorescence greater than
ers 5′-TGTTCCCCTGGACTCAGATG-3′ and 5′-GCACTCCAGGGCcytoplasmic fluorescence, 2 for nuclear fluorescence equal to cytoCGACTGCG-3′ in a 2:2:1 ratio, respectively.
plasmic fluorescence, 1 for nuclear fluorescence less than cytoplasmic
Mouse phenotyping and tissue collection. Every 2 weeks beginning
fluorescence, and 0 for nuclear fluorescence much less than cytoplasat 8 weeks of age, male mice were weighed and forelimb strength was
mic fluorescence. The reported scores represent data from 50 cells per
measured by grip strength meter (Columbus Instruments). Followtime point. To distinguish between type I and type II fibers, FITC-coning acclimation to the instrument, mice were allowed to grip the trijugated donkey anti-mouse IgM was used against A4.840 and Alexa
angular pull bar with forelimbs only and were then pulled backward
Fluor 555 anti-mouse IgG was used against Ab-2. Fluorescence images
horizontally; the average peak tension value from 5 consecutive grip
were acquired using a Zeiss Axio Imager microscope. To calculate pertrials was reported as the grip strength for each mouse. Disease onset
centage of AR aggregation, AR-positive nuclear puncta were manually
was defined as the age at which grip strength was 10% less than the
counted and divided by the total number of nuclei as quantified by
mean of age-matched controls. Skeletal muscles (quadriceps, gastrocImageJ (NIH). To calculate fiber type size, the cross-sectional area of
nemius, soleus, TA, LABC), spinal cord, testis, and seminal vesicles
each fiber within a ×40 field was quantified in triplicate using ImageJ,
were collected from adult males 13 to 15 weeks old and weighed or
and fiber type was discriminated by antibody stain.

Table 1. Significantly enriched Gene Ontology categories related to
mitochondria and energy metabolism
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Orchiectomy. Adult male mice underwent orchiectomy following
induction of anesthesia by 5% isoflurane and maintenance by 1.5%
to 2% isoflurane. The abdomen was cleaned and shaved, and a 5-mm
incision was made at the level of the hind legs. The vas deferens and
spermatic cord were visualized, separated, and ligated with nonabsorbable silk sutures. The testes were removed, and the incision was
closed with absorbable surgical suture. Carpofen was given daily at
5 μg/g body weight by s.c. injection for 3 days after surgery. Three
weeks after surgery, mice were treated with 200 μg testosterone propionate (Sigma-Aldrich) or sesame oil by i.p. injection. Tissue was harvested 16 hours after injection and stored in liquid nitrogen.
Gene-expression analysis. Total RNA was extracted from PC12 cells
and from testes, prostate, quadriceps, and soleus muscles from mice
with Trizol (Sigma-Aldrich). The RNA samples were then reverse transcribed with High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) according to the manufacturer’s recommendations. qPCR
was carried out using FastStart TaqMan Probe Master Mix (Roche) on
software supplied with a 7500 Real-Time PCR SDS System (Applied
Biosystems) and using gene-specific primers with FAM-labeled probes
from Applied Biosystems (Mouse: Ar, Mm00442688_m1; Chrna1,
Mm00431627_m1; Errfi1, Mm00505292_m1; Fkbp5, Mm00487401_
m1; Hsd3b1, Mm00476184_g1; Igf1r, Mm00802831_m1; Irs2,
Mm03038438_m1; Myod1, Mm00499518_m1; Myog, Mm00446194_
m1; Nkx3-1, Mm00440479_m1; Pbsn, Mm00444381_m1; Spdef,
Mm00600221_m1; Steap4, Mm00475405_m1; Wipi1, Mm00461219_
m1; Zbtb10, Mm01281740_m1. Rat: Baiap2, Rn00589411_m1; Chst1,
Rn01484520_m1; Ppard, Rn00565707_m1). Relative expression levels were calculated by normalizing to the expression of 18S rRNA. For
GeneChip microarray analysis, cDNA samples from PC12 cells were
applied to an Affymetrix Mouse Gene ST 2.1 Plate by the University
of Michigan MicroArray Core. For RNA-Seq, cDNA was prepared into
sequencer-ready fragment libraries using the Illumina TruSeq mRNASeq Sample Prep Kit according to the manufacturer’s recommended
protocols and sequenced on the Illumina HiSeq 2000 using the manufacturer’s recommended protocols for paired-end, 100 nt sequencing.
Samples were multiplexed into pools of 6 samples each, and each pool
was sequenced on 1 lane of the sequencer. All original microarray and
RNA-Seq data were deposited in the NCBI’s Gene Expression Omnibus (microarray data, GEO GSE50383; RNA-Seq data, GSE60691).
Statistics. To determine statistical significance, data sets were
analyzed using unpaired 2-tailed Student’s t test, ANOVA with Newman-Keuls multiple comparison test, or Mantel-Cox log-rank test in
Prism 6 (GraphPad). Differences between means were defined as significant at P < 0.05.
For GeneChip analysis, probe data were inspected for quality
control by signal density distribution and normalized unscaled SEM
estimates. Relative expression values were calculated using a robust
multiarray average (RMA), with oligo and limma packages of biocon1. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000;23:217–247.
2. Kennedy WR, Alter M, Sung JH. Progressive
proximal spinal and bulbar muscular atrophy of
late onset. A sex-linked recessive trait. Neurology.
1968;18(7):671–680.
3. Katsuno M, et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in

ductor implemented in the R statistical environment; P values were
adjusted for multiple comparisons using FDR as described previously
(61–64). Expression values were also inspected for quality control by
principal components analysis. Genes were considered significantly
responsive to androgen if they demonstrated a 1.5-fold or greater
activation or repression in the R1881-treated samples compared with
controls and an adjusted P value of 0.05 or less. Genes selected in this
manner and relevant information (probe set ID, statistics, expression
values, gene name, symbol, and links to online databases) were output
into Excel for ranking by fold change values and determining the numbers used for Venn diagrams.
For RNA-Seq, the software package Tuxedo Suite was used for
alignment, differential expression analysis, and postanalysis diagnostics (65–67). The reference transcriptome (UCSC mm10) (http://
genome.ucsc.edu/) was used for alignment. Expression quantitation
and differential expression analysis were performed using CuffDiff
(Cufflinks version 2.1.1). Genes and transcripts were identified as differentially expressed based on 3 criteria: test status = OK, FDR <0.05,
and fold change ≥ 1.5. Analysis of differentially expressed genes to
identify significantly enriched functional categories was performed
using DAVID. The heat map was plotted in R using the gplots and
RColorBrewer packages.
Study approval. The University of Michigan Committee on Use
and Care of Animals approved all procedures involving mice in compliance with the Guide for the Care and Use of Laboratory Animals (8th
ed. National Academies Press. Revised 2011).
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